8-K: Certara Announces Preliminary Q4 and Full Year 2024 Results, Exceeds Bookings Expectations

Certara reports preliminary fourth quarter and full year 2024 financial results, showing strong growth in revenue and bookings, and confirms adjusted EBITDA within the previously guided range.

Summary

• Certara has released preliminary financial results for the fourth quarter and full year of 2024.
• The company's full-year revenue reached $384.4 million, an 8% increase compared to $354.3 million in 2023.
• Full-year bookings totaled $445.3 million, an 11% increase from $402.3 million in the previous year.
• Software revenue for the full year grew by 18% to $155.0 million, while services revenue increased by 3% to $229.4 million.
• For the fourth quarter, revenue was $99.7 million, a 13% increase from $88.0 million in Q4 2023.
• Fourth-quarter bookings were $144.5 million, a 22% increase compared to $118.9 million in the same period last year.
• Software bookings in Q4 grew by 38% to $59.7 million, and services bookings increased by 12% to $84.9 million.
• The acquisition of Chemaxon contributed $5.9 million in revenue and $11.0 million in bookings to the preliminary results.
• Certara confirms that its adjusted EBITDA for the full year is expected to be within the previously guided range of $120 million to $124 million.
• These results are preliminary and unaudited, and may differ from the final figures.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in revenue and bookings, particularly in the software segment. The company is also meeting its EBITDA guidance. However, the preliminary nature of the results and the inherent risks in the industry temper the overall sentiment slightly.

Positives

• The company experienced strong growth in both revenue and bookings for the full year and fourth quarter of 2024.
• Software revenue and bookings showed particularly strong growth, indicating a positive trend in that segment.
• The acquisition of Chemaxon has positively contributed to the company's revenue and bookings.
• The company is on track to meet its adjusted EBITDA guidance for the full year.

Negatives

• The preliminary nature of the results means that the final figures may differ, potentially materially, from the reported estimates.
• Services revenue growth was lower than software revenue growth, at 3% for the full year and 7% for the fourth quarter.

Risks

• The preliminary results are unaudited and subject to change, which could materially impact the final financial statements.
• The company's future performance is subject to various risks, including competition, regulatory changes, and economic conditions.
• There are risks associated with the integration of acquisitions, such as Chemaxon.
• The company's ability to accurately estimate costs associated with fixed-fee contracts is a potential risk.
• The company's reliance on third-party providers for software solutions and data storage poses operational risks.
• There are risks related to the use of artificial intelligence and machine learning in their products and services.
• The company faces risks related to litigation and the protection of its intellectual property.

Future Outlook

The company expects adjusted EBITDA for the full year of 2024 to be within the previously disclosed guidance range of $120 million to $124 million. The company will continue to use its website to disclose material information.

Management Comments

• Certara management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025.

Industry Context

Certara's results reflect the ongoing demand for model-informed drug development solutions within the biopharmaceutical industry. The growth in software revenue and bookings suggests a strong adoption of their technology offerings. The acquisition of Chemaxon further strengthens their position in the market.

Comparison to Industry Standards

• Certara's 8% revenue growth for the full year is a solid performance in the context of the broader pharmaceutical technology sector, which has seen varied growth rates depending on the specific segment.
• Companies like Simulations Plus (SLP) and Schrodinger (SDGR) are comparators in the biosimulation space, and their growth rates and financial metrics will be important to compare against Certara's final results.
• The 11% growth in bookings suggests a healthy pipeline of future revenue, which is a key metric for companies in this sector.
• The 18% growth in software revenue is particularly strong, indicating a successful transition to a more software-centric business model, which is a trend in the industry.
• The adjusted EBITDA guidance of $120 million to $124 million is within the expected range for a company of this size and stage of development.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue and bookings growth.
• Employees may be encouraged by the company's positive performance and growth prospects.
• Customers will benefit from the company's continued investment in its software and services.
• Suppliers and creditors will likely view the company's financial health favorably.

Next Steps

• The company will finalize its financial and accounting procedures for the fourth quarter and full year of 2024.
• The company will publicly disclose its consolidated financial statements for the fourth quarter and full year.
• Certara management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025.

Key Dates

Keywords

Certara, Financial Results, Revenue, Bookings, EBITDA, Software, Services, Acquisition, Chemaxon, Model-Informed Drug Development